Literature DB >> 7599199

Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype.

J A Morgan-Hughes1, M G Sweeney, J M Cooper, S R Hammans, M Brockington, A H Schapira, A E Harding, J B Clark.   

Abstract

This study examines the relationship of genotype to phenotype in 14 unselected patients who were found to harbour the A3243G transition in the mitochondrial transfer RNALeu(UUR) gene commonly associated with the syndrome of mitochondrial encephalopathy, lactic acidosis and strokes (MELAS). Only 6 of the 14 cases (43%) had seizures and recurrent strokes, the core clinical features of the MELAS phenotype. Of the remaining cases, four had an encephalomyopathy with deafness, ataxia and dementia, two had syndromes with progressive external ophthalmoplegia and two had limb weakness alone. Even within the MELAS subgroup, the majority of patients had one or more clinical manifestations considered to be atypical of the MELAS syndrome. They included developmental delay, ophthalmoparesis, pigmentary retinopathy and intestinal pseudo-obstruction. The proportion of mutant mitochondrial DNA (mtDNA) in muscle was generally higher in patients with recurrent strokes than in those without strokes, the highest levels being observed in MELAS cases with early onset disease. Studies of isolated muscle mitochondria identified a range of respiratory chain abnormalities mostly involving Complex I; immunoblots of Complex I in 3 of 10 cases showed selective loss of specific subunits encoded by nuclear genes. In the group as a whole, however, no clear correlations were observed between the severity or extent of the respiratory chain abnormality and clinical phenotype or the proportion of mutant mtDNA in biopsied skeletal muscle. These discrepancies suggest that, in patients harbouring the common MELAS3243 mutation, differences in heteroplasmy and the proportions of mutant mtDNA may not be the sole determinants of disease expression and that additional genetic mechanisms are involved in defining the range of clinical and biochemical phenotypes associated with this aberrant mitochondrial genome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599199     DOI: 10.1016/0925-4439(95)00020-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

Review 1.  NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance.

Authors:  V Calabrese; T E Bates; A M Stella
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 2.  Mitochondrial threshold effects.

Authors:  Rodrigue Rossignol; Benjamin Faustin; Christophe Rocher; Monique Malgat; Jean-Pierre Mazat; Thierry Letellier
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

Review 3.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 4.  Altered metabolism and mitochondrial genome in prostate cancer.

Authors:  G D Dakubo; R L Parr; L C Costello; R B Franklin; R E Thayer
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Conventional MRI and MR spectroscopy in nonclassical mitochondrial disease: report of three patients with mitochondrial DNA deletion.

Authors:  Leonardo Vedolin; Carolina Fischinger Moura de Souza; Rogério Schwark Silveira; Bianca Cunha Lopes; Leticia Saldanha Laybauer; Maria Luiza Saraiva Pereira; Roberto Giugliani
Journal:  Childs Nerv Syst       Date:  2006-03-22       Impact factor: 1.475

Review 6.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Gene expression profiling of skeletal muscle in exercise-trained and sedentary rats with inborn high and low VO2max.

Authors:  Anja Bye; Morten A Høydal; Daniele Catalucci; Mette Langaas; Ole Johan Kemi; Vidar Beisvag; Lauren G Koch; Steven L Britton; Øyvind Ellingsen; Ulrik Wisløff
Journal:  Physiol Genomics       Date:  2008-09-09       Impact factor: 3.107

8.  Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population.

Authors:  K Majamaa; J S Moilanen; S Uimonen; A M Remes; P I Salmela; M Kärppä; K A Majamaa-Voltti; H Rusanen; M Sorri; K J Peuhkurinen; I E Hassinen
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 9.  Mitochondrial dysfunction in neurodegenerative diseases.

Authors:  Anthony H V Schapira
Journal:  Neurochem Res       Date:  2008-11-08       Impact factor: 3.996

Review 10.  Mitochondrial Protein Translation: Emerging Roles and Clinical Significance in Disease.

Authors:  Fei Wang; Deyu Zhang; Dejiu Zhang; Peifeng Li; Yanyan Gao
Journal:  Front Cell Dev Biol       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.